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Background: Recent studies in Guyana and Suriname unveiled diminished efficacy of artemisinin derivatives based
on day-3 parasitaemia. The migrant characteristics of the population at risk and the potential development of
resistance pose a serious health threat in the region. Assessment of factors that may have contributed to this
situation is warranted, and analysis of the data generated in those countries on quality and pharmaceutical
managements of anti-malarials may contribute to a better understanding of this occurrence.
Methods: Data on malaria medicine quality and pharmaceutical management, generated in the context of the
Amazon Malaria Initiative (AMI), was reviewed and discussed.
Results: Numerous substandard artemisinin-containing malaria medicines were identified in both countries,
particularly in Guyana, where a larger number and variety of anti-malarials were sampled. Poor quality was more
frequent in the private and informal sector than in the public sector, posing a greater threat to the populations at
risk, which are mostly located in hard to reach areas with scarce public facilities. Stock-outs identified in the public
sector in Guyana could enhance the need to access those alternative sectors, exacerbating the risk of utilizing poor
quality medicines. The availability of monotherapies and other non-recommended therapies for Plasmodium
falciparum malaria, could also have contributed to the diminished efficacy. The type of quality deficiencies
identified -reduced content of active pharmaceutical ingredient (API) and/or poor dissolution- and the irrational use
of non-recommended treatments could result in non-sustained or lower levels of API in blood, favouring survival of
more resistant mutants by exposing parasites to sub-lethal doses of the active ingredient.
Conclusions: The quality of malaria medicines and the availability and use of non-recommended treatments could
have played a role in the diminished efficacy of artemisinin derivatives described in Guyana and Suriname. However,
also other factors need to be considered and a more comprehensive and extensive assessment on quality and
pharmaceutical management is necessary to establish a tighter cause-effect correlation. Nevertheless, relevant
authorities in these and neighbouring countries should take into consideration the reviewed data to properly
address the problem when implementing corrective actions.Background
Artemisinin derivative resistance was reported initially in
Southeast Asia [1,2], and subsequently the World Health
Organization (WHO) developed two important docu-
ments addressing global reports on artemisinin resist-
ance and resistance containment plans [3,4]. Two recent* Correspondence: vsp@usp.org
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unless otherwise stated.anti-malarial drug efficacy studies performed with
artemether-lumefantrine combinations in Guyana and
Suriname show higher parasitaemia levels at day 3 than
those encountered in previous years [5,6]. Although
these data were not considered definitive evidence of ar-
temisinin resistance and did not merit the designation of
these as tier 1 countries, it was pointed out that resist-
ance in Southeast Asia showed initially a similar trend
[7]. Updated information on the status of malaria in
both countries is available in a recent WHO report [8].
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miners in both countries, as it has been documented in
a recent review [9] for Suriname and in a publication
that highlighted the risk of emergence of resistance to
artemisinin derivatives in French Guyana [10]. As indi-
cated in [11], similar populations at risk are found in
Guyana, including the west border neighboring with
Venezuela and Brazil. Taking into consideration the mi-
grant characteristics of the population at risk, if resist-
ance appears, it may rapidly spread into neighboring
countries and beyond.
These findings in Guyana and Suriname prompt the
urgent need to perform a thorough analysis of the condi-
tions and behaviours that may have contributed to this
occurrence, which could result in the impairment of P.
falciparum malaria therapy. The regional and global
consequences of resistance to artemisinin derivatives
cannot be overstated, particularly because, as of today,
there is no effective comparable alternative.
Management Sciences for Health (MSH) and the
United States Pharmacopeial Convention (USP) have
been involved in the Amazon Malaria Initiative (AMI)
since the early 2000s, through collaborative agreements
established with the United States Agency for Inter-
national Development (USAID). The ‘Systems for Im-
proved Access to Pharmaceuticals and Services’ (SIAPS/
MSH) and the ‘Promoting the Quality of Medicines’
(PQM/USP) programmes provide technical assistance to
improve countries’ pharmaceutical management and
their quality assurance and quality control systems.
Poor quality medicines, irrational use, and/or lack of
adherence to treatment regimens could be factors con-
tributing to the onset of microbial resistance. Therefore,
it was considered appropriate to re-examine relevant in-
formation reported previously under AMI by PQM and
SIAPS for Guyana and Suriname [11-14] to see whether
it hints at factors that could have contributed to the effi-
cacy results reported subsequently in the region. The in-
clusion of Brazil information is warranted because the
three countries share endemic border areas with large
mobile mine-working populations.
Methods
Publicly available information, mostly generated through
PQM and SIAPS activities in AMI, was reviewed and
assessed for information on malaria medicine’s quality
and pharmaceutical management. Additional data for
review was gathered through literature searches at
PubMed.
Results
Assessment of medicine’s quality information
Though the quality studies shed light on availability of
non-recommended treatments and uncovered extensivecommercialization of anti-malarials in the private and
informal market, this article will focus only on available
quality data for medicines containing artemisinin deriva-
tives collected in the public, private and informal sectors
in Guyana, Suriname and Brazil. It is of note that the
first-line treatment for P. falciparum malaria in Guyana
and Suriname is the fixed dose combination (FDC) of
artemeter-lumefantrine, while Brazil utilizes also an
artesunate-mefloquine FDC [8].
Quality of anti-malarials in the public sector in Brazil and
Guyana
For the purpose of performing quality control, AMI
countries collected anti-malarial medicines between
2005 and 2010. The results have been reported in [12],
which also contains detailed information on the medi-
cines collected and the sampling methodology, as well as
failures percentages by country and type of medicine.
Most of the medicines collected in Brazil (301/313 be-
tween 2006 and 2008) and Guyana (220/289 between
2007 and 2010) were sampled in the public sector. Al-
though the report provides information on the results
obtained with screening tests in the field, in Brazil and
Guyana –following protocol– failed samples and a sub-
set of passing samples were reanalyzed for certain tests
at the Official Medicine Control Laboratory (OMCL). In
the majority of the cases, there was concordance be-
tween the field tests and those repeated at the OMCL
(see table four in [12]). Artemisinin derivatives com-
prised four of the anti-malarials collected in Brazil and
92 of those collected in Guyana. In the case of Suriname,
20 anti-malarials were collected in 2007; 15 were
artemisinin-containing medicines. Because samples in
Suriname were collected in the informal sector, results
will be discussed in the following section.
In Brazil and Guyana, medicines were visually inspected
and assessed for disintegration, identity, content, and
impurities (the three latter through thin layer chroma-
tography (TLC)). These are tests that require minimal
equipment and can be performed in the field. The per-
centage of anti-malarials that failed quality control tests
in Brazil and Guyana were 6.4 and 7.3%, respectively,
of which disintegration and TLC failures accounted
for 4.5% in each country. However, no failures were
reported in disintegration or TLC for artemisinin deriv-
atives. The only type of failure found in artemisinin-
containing medicines in both countries was that some
samples were beyond their expiry date. For all anti-
malarial medicines tested in Brazil (313), six (1.9%) were
expired, among the latter only one artesunate. In the
case of Guyana, from 289 samples, 8 (2.8%) were ex-
pired, and among the latter three artemether and three
FDC of artemether and lumefantrine. Based on the re-
sults discussed in this section, the quality of anti-
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parently was not a major risk factor for lesser artemisi-
nin efficacy.
Quality of anti-malarials in the private and informal sector
in Guyana and Suriname
For information on the medicines collected (Active
Pharmaceutical Ingredient-API, and sector) and the
sampling methodology utilized in the Guyana and
Suriname study see [11]. The samples were analyzed at
laboratories operating in compliance with internationally
recognized standards (Peru OMCL: ISO:EIC 17025:2005
accreditation and WHO prequalification, and USP: ISO:
EIC 17025:2005 accreditation). All collected medicines
were analysed through the comprehensive battery of val-
idated methodologies detailed in [11], not the field tests
utilized in the studies described in the section above.
This allowed for better accuracy in the measurement of
content and impurities and also for the assessment of
additional quality attributes such as dissolution and uni-
formity of content. As discussed below, these sectors are
the ones more readily available to the migratory mining
population, which constituted the majority of malaria
patients assessed during the efficacy studies that showed
higher parasitaemia after three days of treatment with an
artemisinin derivative.
Guyana
Malaria medicines were sampled in the private and in-
formal sectors in 2009. From these, 42% (32/77) were
collected in the private sector and 58% (45/77) in the in-
formal sector. In total, 46 samples (60%) were collected
in the three high malaria incidence regions, while 31
samples (40%) were from three non-endemic ‘source’ re-
gions; the latter being regions with urban centres where
people purchase medicine before travelling to the more
remote endemic areas. Therefore, medicines from both
sectors and types of regions were more or less equally
represented in this study. Most of the samples (64%;
40/77) contained artemisinin derivatives, of which 7.5%
(3/40) were monotherapy (artesunate).
The artemisinin-containing medicines collected in-
cluded a monotherapy (Artesunate) and fixed-dose com-
binations (Artecom: dihydroartemisinin, piperaquine,
trimethoprim, primaquine; Artemos-40: dihydroartemisi-
nin, piperaquine, trimethoprim; Co-Ariante: artesunate,
sulphamethoxypyrazine, pyrimethamine; Artemos-Plus:
artemether, lumefantrine) containing artemisinin deri-
vatives. Except for Artemos-Plus, none of the other
artemisinin-containing medicines collected were in-
cluded in the anti-malarial treatment policy of the coun-
try, and Artecom®, prevalent among all anti-malarials
collected (26/77), is not even registered in Guyana. A
fixed-dose combination of dihydroartemisinin, piperaquineand trimethoprim was also a prevalent medicine found
and collected (34%; 26/77).
From all the medicines sampled in the private and in-
formal market, 58% (45/77) failed quality control testing,
which is a significantly higher percentage than the 7.3%
discussed above for the public sector. Two factors con-
tributed, in part, to this larger number: (a) All Artecom
samples (26) failed visual inspection because of incom-
plete information on the primaquine tablet content in
the insert, and (b) Failures in Uniformity of Dosage
Units, some impurities and dissolution are not assessed
with the field screening tests utilized in [12]. However,
even if from the total of 45 failures, that could have been
detected with the a field screening test (TLC), the per-
centage failing would be 17% (13/77), still significantly
higher than the 4.5% (13/289) reported for medicines
collected mostly in the public sector [12]. Thus, one
may conclude that the anti-malarials commercialized in
the private and the informal sectors represent a much
higher risk for the population than those provided free
of charge at public sector facilities.
More important in the context of potential onset of re-
sistance to artemisinin, is that 67% (33/45) of the failures
identified in the private and informal sector were in
artemisinin-containing medicines. Some of those fail-
ures, such as content and dissolution, could result in di-
minished levels of active pharmaceutical ingredients in
the blood stream. All the samples collected from four
out of five different artemisinin-containing medicines
failed. Although no further investigation was done on
the artemisinin-containing medicines that failed, based
on the deviations from the declared content or their
claimed source, none of them could be considered,
prima facie, counterfeits. These results show an add-
itional threat that malaria patients face in endemic min-
ing areas, where private and informal facilities are
prevalent and public sector facilities may be difficult to
access.
For all anti-malarials, the risk of purchasing poor quality
medicines existed both in the private sector (34%; 11/32)
and the informal sector (16%; 7/45), and were equally
prevalent in endemic regions (24%; 11/46) and non-
endemic source regions (23%; 7/31). In endemic regions,
almost twice as many samples (seven) failed in the infor-
mal sector than in the private sector (four), and in non-
endemic source regions, all failures (seven) were identi-
fied in the private sector. Thus, based on these findings
there is a clear risk of purchasing poor quality malaria
medicines in the private or informal sector, both in en-
demic areas as well as non-endemic regions.
Suriname
The results reported in [12] in the informal sector
showed no failures, though this data should be taken
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misinin derivative, 12 had dihydroartemisinin, one as a
monotherapy and 11 as the fixed-dose combinations
dihydroartemisinin, piperaquine and trimethoprim; for
those, only disintegration was assessed because the field
test for TLC was not available at the time. In addition,
the paucity of samples in Suriname (20 in 2007) pre-
cludes making any generalization for this country based
on that sole report.
In Suriname, medicines were collected during 2009
only in facilities from the informal sector [11], mostly
along rivers that constitute the supply-line in mining
areas; some samples were collected also in the capital,
Paramaribo City. The prevalence of Artecom® in this
sector was also very high, constituting 86% (49/57) of all
sampled medicines, and those were analysed at USP.
Of note is that three of the eight lots of Artecom® sam-
pled in Suriname had the same lot number as those
sampled in Guyana. The existence of the same lots in
the two countries would suggest that there is commerce
of medicine across borders and/or that supplier(s) of this
unregistered medicine work across borders. All Arte-
com® samples failed visual inspection because they
lacked information on the content of the co-packaged
primaquine tablet, though the co-packaged fixed-dose
combination tablets passed analytical testing.
Based on these assessments, quality does not seem to
be a risk factor for the most prevalent medicine col-
lected. However, as discussed below, the risk posed by
this extensively utilized non-registered medicine is re-
lated to irrational use and lack of adherence to treatment
guidelines.
Assessment of pharmaceutical management information
Supply of anti-malarials in the public sector
As reported in the June 2013 issue of the quarterly re-
gional monitoring of anti-malarials bulletin, 56% of med-
icines normally found in the central warehouse of
Guyana was stocked out [13]. Supply issues, particularly
in Guyana, could create a discontinuous supply of medi-
cines at the point of delivery and encourage patients to
access these medicines in the more risky private and in-
formal sectors.
Availability of anti-malarials in the private and informal
sector
In AMI countries, free treatment is provided to patients
by the Ministries of Health. However, as clearly uncov-
ered by the quality studies discussed above, there is
ample commercialization of anti-malarials beyond the
public sector. The risk posed by that is reflected not only
in the quality of those products, but in the access to
medicines that are not registered in the countries and
for which there is no evidence of being efficacious. Inaddition to the improper use of those products, there
was evidence of availability of artemisinin-derivatives
monotherapy, whose use is against WHO guidelines.
Commercialization of anti-malarials is also well docu-
mented in Guyana in an anti-malarials availability as-
sessment performed in the public and private sector
from several AMI countries [14]. More than 90% of the
number of units of anti-malarials distributed in the pri-
vate sector contained artemisinin derivatives that were
not registered in the country.
It is worth noting that in terms of the availability and
use of anti-malarials in these sectors, that similar behav-
iours and environment are described for the population
at risk in Suriname [9] and French Guyana [10] and
most probably also applies to Guyana.
Conclusions
The evidence available for Guyana and Suriname identi-
fies several risk factors that individually, and even more
collectively, may have had a role in the reduced efficacy
of artemisinin derivatives recently found in these two
countries. A high percentage of anti-malarials collected
in Guyana had quality problems. Furthermore, in both
countries, non-recommended treatments including arte-
misinin monotherapy and non-registered artemisinin de-
rivatives were readily available beyond the public sector,
in areas where patients and travellers are more likely
to use the private and informal sector to buy these
medicines.
Although only mefloquine and quinine samples were
identified that had no activity ingredient at all, several
artemisinin derivative-containing medicines had content
and/or dissolution problems. These type of failures could
result in lower than required therapeutic levels in pa-
tients’ blood, and dosage below the optimal level will kill
the susceptible parasites while the drug-resistant para-
sites survive and contribute to their spread [4]. Of note
is that the poor quality anti-malarials were found mostly
in the private and informal sectors, which are prevalent
and easily accessible to patients in endemic areas.
In addition to quality problems, these studies identi-
fied artemisinin-derivative monotherapy and numerous
unregistered artemisinin-based combination therapies
(ACT). The former could cause higher survival rates of
the less sensitive forms of the parasite due to their rapid
clearance from the blood. Regarding the latter, even as-
suming that the non-registered ACT would be effica-
cious (which has to be proven for this population), lack
of guidance for proper use by patients and lack of adher-
ence to treatment would most probably be associated
with the use of those medicines for shorter times than
required (when febrile episodes subside), which in turn
would result in incomplete elimination of the parasite
and selective survival of resistant strains. Finally, the
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in these countries is consistent with porous borders, as is
the case for the movement of migrant workers. Both fac-
tors may be associated and potentiate the risks of spread-
ing of the parasites less sensitive to artemisinin.
One has to be cautious, however, when interpreting
the quality data reviewed here, and it is important to
consider, amongst other, the following factors: the sam-
ple size of these studies was not very large; sampling size
and sampling methodologies could affect the results
(failure percentages); not all relevant geographic areas
were covered; some of the data discussed in this article
is not very recent. Regarding the latter, the authors are
not aware of any recent quality monitoring activity per-
formed in risk areas in neither of these two countries. It
is also important to highlight that other factors not con-
sidered in this article may have had a significant impact
on the efficacy of the treatment, particularly behaviour
patterns in population at risk such as migrant workers
travelling across international borders. In addition, these
are hard to reach geographical areas poorly covered by
public health services, resulting in treatment and pa-
tients outreach far from optimal. Some of these prob-
lems are discussed in [9,10], especially for Suriname
where diminished efficacy has been observed despite an
otherwise effective and comprehensive approach to
reach target populations and combat malaria [9].
To conclude, the evidence and information for the risk
factors assessed here have been in the public domain for
years. Now that higher parasitaemia after three days of
treatment has been uncovered and the risk of resistance
unveiled, it is expected that health authorities, individu-
ally and collectively, will intensify national and regional
efforts to address the potential contributing factors de-
scribed in this brief within the context of actions taken
to avoid the onset and prevent the spread of resistance.
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